Download Sample
Schedule a Meeting
NA : +1 804 441 9344
sales@towardshealthcare.com
September 2025
The global polycystic ovary syndrome treatment market size is calculated at US$ 4.83 billion in 2024, grew to US$ 5.15 billion in 2025, and is projected to reach around US$ 4.83 billion by 2034. The market is expanding at a CAGR of 6.56% between 2025 and 2034.
The World Health Organization (WHO) works in collaboration with partners and member states to address PCOS to improve women’s health and reproductive well-being on a global level. The WHO supports the polycystic ovary syndrome treatment market by promoting research on the most effective approaches to prevent, diagnose, and treat infertility due to PCOS. The notable treatments can reduce symptoms of PCOS, which include healthy lifestyle changes, a healthy diet, regular exercise, birth control medicines (contraceptive pills), IVF, surgery, and some other medicines.
| Table | Scope |
| Market Size in 2025 | USD 5.15 Billion |
| Projected Market Size in 2034 | USD 4.83 Billion |
| CAGR (2025 - 2034) | 6.56% |
| Leading Region | North America |
| Market Segmentation | By Treatment Type, By Route of Administration, By End-User/Patient Type, By Revenue Model, By Region |
| Top Key Players | Pfizer Inc., Bayer AG, Teva Pharmaceutical Industries Ltd., Mylan N.V. (Viatris), Cipla Limited, Hetero Labs Limited, Fresenius Kabi AG, Sandoz International GmbH, Sun Pharmaceutical Industries Ltd., Zydus Cadila, Glenmark Pharmaceuticals Ltd., Novartis AG, Aurobindo Pharma Ltd., Dr. Reddy’s Laboratories Ltd., Intas Pharmaceuticals Ltd. |
The polycystic ovary syndrome treatment market refers to the commercialization and adoption of pharmaceuticals, hormonal therapies, nutraceuticals, and lifestyle interventions aimed at managing PCOS symptoms, regulating menstrual cycles, improving fertility, and addressing associated metabolic disorders. PCOS is a complex endocrine disorder affecting women of reproductive age, often associated with infertility, insulin resistance, obesity, and cardiovascular risks. Market growth is driven by the rising prevalence of PCOS, increasing awareness of women’s health, technological advancements in therapeutics, growing demand for fertility treatments, and supportive government initiatives for women’s healthcare.
Artificial intelligence helps with improved diagnosis, risk prediction, personalized treatments, and treatment monitoring. The machine learning algorithms assist AI in the analysis of ultrasound images, genetic markers, hormone profiles, and other patient data, which leads to earlier and more accurate diagnosis of PCOS. AI models can assess related risk factors for PCOS, including cardiovascular disease and diabetes, which allows for early intervention and preventive measures. AI helps in the development of personalized treatment plans, while AI algorithms can assess the effectiveness of early interventions. AI helps researchers to understand the molecular pathophysiology of PCOS, leading to more targeted therapies.
| Sr. No. | Awardee Organization | Funding IC | FY Total Cost by IC |
| 1 | UNIVERSITY OF MICHIGAN AT ANN ARBOR | National Institute of General Medical Sciences (NIGMS) | $405,600.00 |
| 2 | BRIGHAM AND WOMEN'S HOSPITAL | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | $354,840.00 |
| 3 | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | $416,064.00 |
| 4 | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | $26,468.00 |
| 5 | HENRY FORD HEALTH + MICHIGAN STATE UNIVERSITY HEALTH SCIENCES | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | $1,394,304.00 |
The pharmaceuticals/drugs segment dominated the polycystic ovary syndrome treatment market in 2024, owing to the potential uses of hormonal contraceptives and anti-androgens for treating menstrual irregularities and hyperandrogenism. The ovulation induction agents aid in treating infertility, and insulin-sensitizing agents treat insulin resistance and metabolic issues. Pharmaceuticals are vital in managing the symptoms and health risks related to PCOS.
The combination therapy regimens segment is expected to grow at the fastest CAGR in the market during the forecast period due to its numerous benefits, such as better insulin sensitivity, improved menstrual regularity, and a significant reduction in BMI. It is vital in driving the polycystic ovary syndrome treatment market through the effective management of menstrual cycles and the reduction of hyperandrogenism symptoms. It results in better hormonal profiles and a higher ovulation rate in women.
The oral segment dominated the market in 2024, owing to the potential of oral contraceptives to manage irregular menstrual cycles and hyperandrogenism in women. The ovulation induction medications are preferred by women who are willing to become pregnant by inducing ovulation. The oral administration of medications in PCOS treatment is beneficial in terms of convenience, long-term disease management, and identification of multiple symptoms.
The injectable fertility agents segment is estimated to grow at the fastest rate in the polycystic ovary syndrome treatment market during the predicted timeframe due to their use in ovulation induction, intrauterine insemination (IUI), in vitro fertilization (IVF), and assisted reproductive technology (ART). These are also known as gonadotropins, which include follicle-stimulating hormone (FSH), luteinizing hormone (LH), and human chorionic gonadotropin (hCG), used for fertility treatment in PCOS. They are good solutions in case of failure of first-line oral medications, such as letrozole or clomiphene citrate, to induce ovulation.
The women of reproductive age segment dominated the polycystic ovary syndrome treatment market in 2024, owing to the key functions of PCOS treatment in managing symptoms of PCOS based on individual patient needs and health goals. The common therapies to treat PCOS in non-pregnant women are combined hormonal contraceptives (CHCs), anti-androgen medications, and metformin. Whereas ovulation induction medications, metformin, and in vitro fertilization (IVF) are common treatments for women desiring pregnancy.
The adolescents & young women segment is anticipated to grow at a notable rate in the market during the upcoming period due to improvements in insulin sensitivity, reduction of androgen levels, restoration of menstrual regularity, and reduction of metabolic risks using metformin. The other treatments driving the polycystic ovary syndrome treatment market include monotherapy and combination therapy, which are used in adolescents with other medications to increase the efficacy of treatment. Metformin is widely used to manage metabolic complications and address insulin resistance.
The prescription drug sales segment dominated the market in 2024, owing to the increased focus of pharmaceutical representatives on promoting and selling pharmaceutical products to healthcare professionals who further sell those products to their patients. This sale empowers healthcare professionals by educating them to build relationships. The increased shift from sales to partnerships, increased focus on digital marketing, and emphasis on ethics and compliance will drive the future of prescription drug sales in the polycystic ovary syndrome treatment market.
The telemedicine & online treatment platforms segment is predicted to grow at a rapid rate in the market during the studied period due to increased access to healthcare and improved patient and provider efficiency. The enhanced patient care and patient management ensure continuity of care and effective management of chronic conditions. These platforms provide mental and behavioral health support to patients by delivering remote healthcare services.
North America dominated the market in 2024, owing to high awareness, advanced healthcare infrastructure, and early diagnosis. The polycystic ovary syndrome treatment market in North America is expanding at a significant growth rate, along with the research studies of organizations like the National Institutes of Health (NIH). According to the recent data from the NIH, AI and machine learning can potentially diagnose PCOS and detect common hormone disorders. The large-scale national government programs and government-funded research led to improved care and awareness among the North American people. The American Society for Reproductive Medicine (ASRM) provided recommendations for the assessment and management of PCOS.
The major driving forces for the growth of the polycystic ovary syndrome treatment market in the U.S. are federal government initiatives, clinical trials, international guidelines, and PCOS conferences. The federal efforts were taken for women’s health research, which has accelerated research and development across the U.S. The Department of Health and Human Services (HHS) announced a $100 million initiative to address research-neglected areas of women’s health.
In October 2024, the Government of Canada announced a national women’s health research initiative (NWHRI) to advance the research program that addresses potential areas of women’s health and ensures improved healthcare outcomes.
The Government of Canada announced its support for seven research projects to accelerate the growth of the polycystic ovary syndrome treatment market through healthy living and the prevention of chronic diseases. The Canadian Institutes of Health Research (CIHR) led the national women’s health research initiative through biomedical discovery grants and operating grants.
Asia Pacific is expected to grow at the fastest CAGR in the market during the forecast period due to growing prevalence, increased women’s health initiatives, and expanding healthcare access. The governments of Asian Pacific countries, like India, focused on expanding national health campaigns and promoting PCOS-related research and awareness.
The polycystic ovary syndrome treatment market’s growth in the Asia Pacific is also accelerated by a continued focus on improving women’s health and the development of international guidelines for clinical research. The international conferences held on PCOS and fertility concepts have united several research experts to display the latest advancements in symptom management and treatment. This region continues its efforts to improve PCOS diagnosis and treatment through conferences, guidelines, and awareness campaigns.
Research and pilot projects and health schemes covering PCOS in India promote research, awareness, and holistic management. The Indian government makes efforts to promote lifestyle changes and novel approaches to treatment through research and vaccine campaigns. The polycystic ovary syndrome treatment market is expanding in India through research studies conducted by Indian research institutes, which aim to improve fertility and birth outcomes in Indian women with PCOS.
China’s growth in the market is primarily driven by national-level support for research and health promotion strategies. The collaborations with the WHO and increased focus on preventative health supported government-backed initiatives and research in China. The digital interventions in China help to manage PCOS, which represent a more effective solution than metformin.
The R&D process for the polycystic ovary syndrome treatment market includes discovery and preclinical stage, clinical trials, and holistic approaches and integration.
Key Players: AstraZeneca, Bayer AG, Bristol Myers Squibb, Merck KGaA, Novartis AG, Teva Pharmaceutical Industries.
This encompasses standard therapeutic formulations, emerging therapies, nanomedicine, etc., that focus on personalized pharmacological approaches and lifestyle management.
Key Players: Bayer AG, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Novartis AG, Bristol Myers Squibb.
The integrated care teams support patients with targeted therapies, fertility treatments, diagnosis, monitoring, telehealth services, and mental health services.
Key Players: Allara Health, Veera Health, Pollie, Imana Care, Syrona Health, Gytree.
By Treatment Type
By Route of Administration
By End-User/Patient Type
By Revenue Model
By Region
September 2025
August 2025
July 2025
July 2025